Abstract | BACKGROUND: CASE PRESENTATION: CONCLUSION: Internists, oncologists, endocrinologists, and ophtalmologists should be aware of uveitis as a possible complication of zoledronic acid therapy. Patients should be instructed to report immediately to their physicians and treatment with topical prednisone and atropine eyedrops should be instituted immediately at the onset of symptoms. This report documents anterior uveitis as a complication of zoledronic acid therapy. This reaction could be an idiosyncratic one but further research may shed more light on the etiology.
|
Authors | Nagi S El Saghir, Zaher K Otrock, Jamal H Bleik |
Journal | BMC cancer
(BMC Cancer)
Vol. 5
Pg. 156
(Dec 06 2005)
ISSN: 1471-2407 [Electronic] England |
PMID | 16332258
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- Zoledronic Acid
|
Topics |
- Bone Density Conservation Agents
(adverse effects, therapeutic use)
- Breast Neoplasms
(complications)
- Diphosphonates
(adverse effects, therapeutic use)
- Female
- Humans
- Imidazoles
(adverse effects, therapeutic use)
- Middle Aged
- Osteoporosis
(drug therapy, etiology)
- Uveitis, Anterior
(chemically induced)
- Zoledronic Acid
|